Product Description
PRT3645 is a highly potent, selective and brain penetrant CDK4/6 inhibitor that demonstrated greater than 10x brain penetration compared to approved CDK4/6 agents in preclinical models. (Sourced from: https://preludetx.com/science/discovery-engine/prt3645-cdk4-6/)
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Prelude Therapeutics
Company Location: WILMINGTON DE 19803
Company CEO: Krishna Vaddi
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Singapore, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Breast Cancer|Endometrial Cancer|Glioblastoma|Head and Neck Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Sarcoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRT3645-01 | P1 |
Completed |
Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Mesothelioma|Breast Cancer|Sarcoma|Endometrial Cancer|Glioblastoma |
2024-06-26 |